Literature DB >> 9233752

Therapy of myasthenic crisis.

J Berrouschot1, I Baumann, P Kalischewski, M Sterker, D Schneider.   

Abstract

OBJECTIVES: To investigate the frequency, causes, and characteristic features of the course of isolated myasthenic crisis (defined as acute respiratory failure with the need for mechanical ventilation). To compare the effectiveness of three different therapeutic regimens (i.e., continuous intravenous infusion of pyridostigmine, pyridostigmine plus prednisolone, and plasma exchange) in terms of duration of ventilation and outcome of patients with myasthenic crisis.
DESIGN: Population-based retrospective study covering the period 1970 to 1995.
SETTING: University hospital, center for myasthenia gravis in Saxony, Germany. PATIENTS: Of 235 patients with myasthenia gravis treated at our institution, 44 patients developed a total of 63 myasthenic crises (average annual incidence 2.5%).
INTERVENTIONS: Myasthenic crises were treated with pyridostigmine (n = 24), pyridostigmine plus prednisolone (n = 18), and plasma exchange (n = 21).
MEASUREMENTS AND MAIN RESULTS: There were no significant differences between the three treatment groups with respect to clinical characteristics, duration of mechanical ventilation, complications, and outcome on release from intensive care and after 3 months. Eleven (17%) patients had severe cardiac arrhythmia, which ended fatally for six patients.
CONCLUSIONS: None of the therapeutic regimens applied demonstrated any advantage over the others. All three regimens used were found to be effective and should be applied depending on the circumstances prevailing. Patients with myasthenic crisis must undergo careful cardiac monitoring, and temporary pace-making should be provided where clinically indicated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233752     DOI: 10.1097/00003246-199707000-00027

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  30 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature.

Authors:  R Agarwal; C Reddy; D Gupta
Journal:  Emerg Med J       Date:  2006-01       Impact factor: 2.740

Review 3.  Myasthenic crisis.

Authors:  David Lacomis
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

Review 5.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 6.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

7.  The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis.

Authors:  Jenn-Yu Wu; Ping-Hung Kuo; Pi-Chuan Fan; Huey-Dong Wu; Fuh-Yuan Shih; Pan-Chyr Yang
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

Review 8.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

9.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

10.  Myasthenia gravis presenting as isolated respiratory failure: a case report.

Authors:  Won Hee Kim; Jung Hyun Kim; Eun Kyung Kim; Sang Pil Yun; Kyung Keun Kim; Won Chan Kim; Hye Cheol Jeong
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.